Incyte Stock Price, News & Analysis (NASDAQ:INCY)

$94.63 0.55 (0.58 %)
(As of 01/24/2018 04:21 AM ET)
Previous Close$94.08
Today's Range$93.88 - $95.16
52-Week Range$88.81 - $153.15
Volume1.41 million shs
Average Volume1.97 million shs
Market Capitalization$19.97 billion
P/E Ratio-118.29
Dividend YieldN/A
Beta0.74

About Incyte (NASDAQ:INCY)

Incyte logoIncyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Receive INCY News and Ratings via Email

Sign-up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:INCY
CUSIP45337C10
Phone+1-302-4986700

Debt

Debt-to-Equity Ratio0.01%
Current Ratio4.82%
Quick Ratio4.81%

Price-To-Earnings

Trailing P/E Ratio-118.2875
Forward P/E Ratio-71.15
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.11 billion
Price / Sales18.06
Cash Flow$0.95 per share
Price / Cash99.67
Book Value$2.23 per share
Price / Book42.43

Profitability

Trailing EPS($0.80)
Net Income$104.22 million
Net Margins-10.90%
Return on Equity-12.91%
Return on Assets-7.41%

Miscellaneous

Employees980
Outstanding Shares211,040,000

Incyte (NASDAQ:INCY) Frequently Asked Questions

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) posted its earnings results on Tuesday, October, 31st. The biopharmaceutical company reported $0.17 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.06 by $0.11. The biopharmaceutical company had revenue of $381.50 million for the quarter, compared to the consensus estimate of $360.34 million. Incyte had a negative net margin of 10.90% and a negative return on equity of 12.91%. The business's quarterly revenue was up 41.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.19 earnings per share. View Incyte's Earnings History.

When will Incyte make its next earnings announcement?

Incyte is scheduled to release their next quarterly earnings announcement on Monday, February, 12th 2018. View Earnings Estimates for Incyte.

Where is Incyte's stock going? Where will Incyte's stock price be in 2018?

22 brokers have issued 1 year price targets for Incyte's shares. Their predictions range from $106.00 to $174.00. On average, they anticipate Incyte's share price to reach $143.00 in the next year. View Analyst Ratings for Incyte.

What are Wall Street analysts saying about Incyte stock?

Here are some recent quotes from research analysts about Incyte stock:

  • 1. According to Zacks Investment Research, "Incyte’s dependence on only Jakafi, for growth is concerning. Lower-than-expected sales would be a huge setback for the company. While we are positive on the company’s efforts to expand Jakafi’s label, any development/regulatory setback could pull down the stock significantly. In addition, Jakafi could face competition from generics. Meanwhile, the oncology market is attracting a lot of attention with several companies inking deals to tap into this high revenue-potential market. Sooner-than-expected entry of generic versions of Jakafi would be a big blow for the company. Though we are pleased with Incyte’s broad pipeline, we note that most candidates are in the mid and early stages of development. Shares have underperformed the industry in the last twelve months." (1/2/2018)
  • 2. Cowen Inc analysts commented, "Over the weekend Incyte presented multiple datasets from a Phase I/II trial of." (6/5/2017)
  • 3. Instinet analysts commented, "Incyte has been incrementally expanding the opportunity for its JAK franchise in oncology and autoimmune. We anticipate near-term upside from novel JAK combos, formulations, and applications in oncology and autoimmune disease. These under-recognized programs represent $25/sh of our target price and, in our view, offer lower-risk opportunities vs. epacadostat." (3/1/2017)
  • 4. Jefferies Group LLC analysts commented, "Solid, unsurprising Valentine's Day 4Q report, with good Jakafi metrics and increasing depth from the maturing pipeline building towards broad, more diversified long-term growth opportunities. We continue to see upside potential in 2017 supported by continued Jakafi execution, IDO data/progress, and bari launch enthusiasm, with scarcity value likely continuing to drive M&A speculation. Adjust tgt to $140 from $136." (2/15/2017)

Are investors shorting Incyte?

Incyte saw a increase in short interest in the month of December. As of December 15th, there was short interest totalling 8,241,237 shares, an increase of 18.2% from the November 30th total of 6,971,562 shares. Based on an average daily trading volume, of 1,559,472 shares, the days-to-cover ratio is currently 5.3 days. Approximately 3.9% of the company's stock are short sold.

Who are some of Incyte's key competitors?

Who are Incyte's key executives?

Incyte's management team includes the folowing people:

  • Herve Hoppenot, Chairman of the Board, President, Chief Executive Officer (Age 57)
  • David W. Gryska, Chief Financial Officer, Executive Vice President (Age 61)
  • Reid M. Huber, Executive Vice President, Chief Scientific Officer (Age 45)
  • Eric H. Siegel, Executive Vice President, General Counsel (Age 52)
  • Paula J. Swain, Executive Vice President - Human Resources (Age 59)
  • Barry P. Flannelly, Executive Vice President and General Manager , US (Age 59)
  • Vijay Iyengar, Executive Vice President, Global Strategy and Corporate Development` (Age 44)
  • Wenqing Yao Ph.D., Executive Vice President, Head of Discovery Chemistry (Age 54)
  • Steven H. Stein M.D., Vice President and Chief Medical Officer (Age 50)
  • Julian C. Baker, Lead Independent Director (Age 50)

Who owns Incyte stock?

Incyte's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Frontier Capital Management Co. LLC (0.40%), Schwab Charles Investment Management Inc. (0.27%), National Pension Service (0.08%), Bank of Montreal Can (0.08%), Chevy Chase Trust Holdings Inc. (0.07%) and Strs Ohio (0.05%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, David W Gryska, Eric H Siegel, Herve Hoppenot, Jean Jacques Bienaime, Julian Baker, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber, Steven H Stein and Vijay K Iyengar. View Institutional Ownership Trends for Incyte.

Who sold Incyte stock? Who is selling Incyte stock?

Incyte's stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Nisa Investment Advisors LLC, Cobiz Wealth LLC, QUANTRES ASSET MANAGEMENT Ltd, Exxonmobil Investment Management Inc. TX, Lau Associates LLC, Fox Run Management L.L.C. and Gateway Investment Advisers LLC. Company insiders that have sold Incyte company stock in the last year include Barry P Flannelly, David W Gryska, Eric H Siegel, Herve Hoppenot, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber, Steven H Stein and Vijay K Iyengar. View Insider Buying and Selling for Incyte.

Who bought Incyte stock? Who is buying Incyte stock?

Incyte's stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Schwab Charles Investment Management Inc., National Pension Service, State of Alaska Department of Revenue, Strs Ohio, Creative Planning, Atria Investments LLC and Berson & Corrado Investment Advisors LLC. Company insiders that have bought Incyte stock in the last two years include Bros Advisors Lp Baker, Jean Jacques Bienaime and Julian Baker. View Insider Buying and Selling for Incyte.

How do I buy Incyte stock?

Shares of Incyte can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Incyte's stock price today?

One share of Incyte stock can currently be purchased for approximately $94.63.

How big of a company is Incyte?

Incyte has a market capitalization of $19.97 billion and generates $1.11 billion in revenue each year. The biopharmaceutical company earns $104.22 million in net income (profit) each year or ($0.80) on an earnings per share basis. Incyte employs 980 workers across the globe.

How can I contact Incyte?

Incyte's mailing address is 1801 Augustine Cut off, WILMINGTON, DE 19803-4404, United States. The biopharmaceutical company can be reached via phone at +1-302-4986700 or via email at [email protected]


MarketBeat Community Rating for Incyte (INCY)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  846 (Vote Outperform)
Underperform Votes:  290 (Vote Underperform)
Total Votes:  1,136
MarketBeat's community ratings are surveys of what our community members think about Incyte and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Incyte (NASDAQ:INCY) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.772.772.822.86
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
18 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
18 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $143.00$143.65$144.70$142.63
Price Target Upside: 53.50% upside50.58% upside26.32% upside7.47% upside

Incyte (NASDAQ:INCY) Consensus Price Target History

Price Target History for Incyte (NASDAQ:INCY)

Incyte (NASDAQ:INCY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/22/2018OppenheimerReiterated RatingHold$120.00 -> $110.00LowView Rating Details
1/3/2018BMO Capital MarketsReiterated RatingBuy$172.00LowView Rating Details
1/2/2018CitigroupReiterated RatingMarket Perform$135.00 -> $120.00HighView Rating Details
1/2/2018Royal Bank of CanadaUpgradeSector Perform -> Outperform$136.00HighView Rating Details
12/12/2017Deutsche BankInitiated CoverageHold$106.00MediumView Rating Details
12/12/2017Raymond James FinancialReiterated RatingBuyMediumView Rating Details
12/5/2017CowenReiterated RatingBuyLowView Rating Details
10/31/2017JPMorgan Chase & Co.Reiterated RatingBuyN/AView Rating Details
10/6/2017Goldman Sachs GroupInitiated CoverageBuy$160.00N/AView Rating Details
10/6/2017Jefferies GroupReiterated RatingBuyN/AView Rating Details
9/13/2017ArgusReiterated RatingBuy$150.00LowView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$135.00MediumView Rating Details
8/2/2017BarclaysReiterated RatingOverweight$180.00 -> $165.00LowView Rating Details
7/16/2017Credit Suisse GroupSet Price TargetBuy$152.00LowView Rating Details
6/28/2017GabelliReiterated RatingBuy$174.00MediumView Rating Details
5/31/2017CIBCBoost Price TargetOutperform$125.00 -> $135.00LowView Rating Details
5/19/2017Morgan StanleyReiterated RatingOverweight$142.00MediumView Rating Details
4/19/2017SunTrust BanksLower Price TargetBuy$160.00 -> $145.00LowView Rating Details
4/17/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Neutral$124.00MediumView Rating Details
3/21/2017William BlairInitiated CoverageOutperformLowView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$148.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
1/18/2017JMP SecuritiesReiterated RatingOutperform$130.00N/AView Rating Details
11/20/2016Leerink SwannReiterated RatingOutperform$101.00 -> $115.00N/AView Rating Details
6/6/2016Brean CapitalReiterated RatingBuyN/AView Rating Details
1/31/2016Bank of AmericaReiterated RatingBuy$145.00 -> $87.00N/AView Rating Details
(Data available from 1/24/2016 forward)

Earnings

Incyte (NASDAQ:INCY) Earnings History and Estimates Chart

Earnings by Quarter for Incyte (NASDAQ:INCY)

Incyte (NASDAQ INCY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/15/2018$0.01N/AView Earnings Details
10/31/2017Q3 2017$0.06$0.17$360.34 million$381.50 millionViewN/AView Earnings Details
8/1/2017Q2 2017($0.05)($0.06)$318.45 million$326.40 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.97)($0.96)$359.19 million$384.08 millionViewListenView Earnings Details
2/14/2017Q416$0.14$0.05$324.90 million$326.00 millionViewListenView Earnings Details
11/1/2016Q316($0.04)$0.11$260.98 million$269.50 millionViewN/AView Earnings Details
8/9/2016Q216($0.02)$0.18$236.91 million$208.00 millionViewN/AView Earnings Details
5/9/2016Q116$0.29$0.12$266.38 million$263.00 millionViewN/AView Earnings Details
2/11/2016Q415$0.09$0.29$223.54 million$243.88 millionViewListenView Earnings Details
11/3/2015Q315($0.41)($0.22)$179.30 million$187.70 millionViewN/AView Earnings Details
8/4/2015Q215($0.11)($0.04)$153.27 million$162.98 millionViewListenView Earnings Details
4/30/2015Q115($0.06)($0.11)$155.21 million$159.30 millionViewListenView Earnings Details
2/12/2015Q414($0.14)($0.22)$138.37 million$106.00 millionViewListenView Earnings Details
10/30/2014Q3$0.02$0.33$149.92 million$198.15 millionViewListenView Earnings Details
7/31/2014Q214($0.09)($0.22)$140.72 million$99.58 millionViewListenView Earnings Details
5/1/2014Q114($0.19)($0.21)$97.70 million$89.80 millionViewListenView Earnings Details
2/12/2014Q413($0.10)($0.15)$98.04 million$97.10 millionViewListenView Earnings Details
10/31/2013Q313($0.13)($0.14)$81.40 million$85.10 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.08$0.05$114.34 million$101.70 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.18)($0.12)$68.16 million$71.10 millionViewListenView Earnings Details
2/14/2013Q4 2012($0.02)$0.14$92.03 million$113.80 millionViewListenView Earnings Details
11/1/2012Q312($0.21)($0.17)$60.61 million$60.50 millionViewN/AView Earnings Details
8/2/2012($0.02)$0.03ViewN/AView Earnings Details
4/26/2012($0.48)($0.36)ViewN/AView Earnings Details
2/15/2012($0.40)($0.44)ViewN/AView Earnings Details
10/27/2011($0.43)($0.42)ViewN/AView Earnings Details
7/28/2011($0.36)($0.41)ViewN/AView Earnings Details
5/3/2011($0.32)($0.21)ViewN/AView Earnings Details
2/10/2011$0.19$0.26ViewN/AView Earnings Details
11/9/2010Q3 2010($0.33)($0.26)ViewN/AView Earnings Details
8/5/2010Q2 2010($0.04)$0.02ViewN/AView Earnings Details
5/6/2010Q1 2010($0.31)($0.27)ViewN/AView Earnings Details
2/18/2010Q4 2009($0.35)($0.41)ViewN/AView Earnings Details
11/5/2009Q3 2009($0.41)($0.39)ViewN/AView Earnings Details
7/30/2009Q2 2009($0.41)($0.41)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.42)($0.41)ViewN/AView Earnings Details
2/18/2009Q4 2008($0.47)($0.50)ViewN/AView Earnings Details
11/6/2008Q3 2008($0.50)($0.49)ViewN/AView Earnings Details
7/29/2008Q2 2008($0.50)($0.54)ViewN/AView Earnings Details
4/30/2008Q1 2008($0.47)($0.48)ViewN/AView Earnings Details
2/14/2008Q4 2007($0.25)($0.26)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Incyte (NASDAQ:INCY) Earnings Estimates

2018 EPS Consensus Estimate: $0.10
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.33)($0.21)($0.25)
Q2 20184($0.06)$0.41$0.11
Q3 20183$0.16$0.47$0.27
Q4 20184($0.13)$0.10($0.02)
Q2 20191$0.65$0.65$0.65
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Incyte (NASDAQ:INCY)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Incyte (NASDAQ INCY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 17.70%
Institutional Ownership Percentage: 90.75%
Insider Trades by Quarter for Incyte (NASDAQ:INCY)
Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Incyte (NASDAQ INCY) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/5/2018David W GryskaInsiderSell6,760$98.87$668,361.2020,752View SEC Filing  
1/2/2018Vijay K IyengarEVPSell5,000$97.26$486,300.00View SEC Filing  
12/1/2017Reid M HuberEVPSell696$98.01$68,214.96View SEC Filing  
11/16/2017Paul A FriedmanDirectorSell28,507$105.24$3,000,076.68View SEC Filing  
11/2/2017David W GryskaInsiderSell3,915$105.63$413,541.45View SEC Filing  
9/18/2017Herve HoppenotPresidentSell70,502$119.45$8,421,463.90View SEC Filing  
9/14/2017Barry P FlannellyEVPSell714$124.25$88,714.5015,496View SEC Filing  
9/8/2017Bros. Advisors Lp BakerDirectorBuy100,000$132.00$13,200,000.00View SEC Filing  
9/5/2017Paul TrowerInsiderSell3,000$138.41$415,230.0014,853View SEC Filing  
9/1/2017Eric H SiegelEVPSell1,820$137.40$250,068.0023,553View SEC Filing  
8/31/2017Paula J SwainEVPSell20,000$140.00$2,800,000.0055,067View SEC Filing  
8/29/2017Steven H SteinEVPSell2,111$125.00$263,875.0018,687View SEC Filing  
8/4/2017Paul TrowerInsiderSell3,000$125.25$375,750.0011,853View SEC Filing  
8/1/2017Eric H SiegelEVPSell1,820$132.92$241,914.4023,553View SEC Filing  
7/20/2017Steven H SteinEVPSell6,485$131.09$850,118.6519,356View SEC Filing  
7/5/2017Paul TrowerInsiderSell3,000$126.18$378,540.0012,148View SEC Filing  
7/3/2017Eric H SiegelEVPSell1,820$126.20$229,684.0020,036View SEC Filing  
6/30/2017David W GryskaInsiderSell599$129.74$77,714.2619,614View SEC Filing  
6/20/2017Steven H SteinEVPSell9,883$125.00$1,235,375.0018,518View SEC Filing  
6/12/2017David W GryskaCFOSell16,756$116.60$1,953,749.6035,771View SEC Filing  
6/5/2017Paul TrowerInsiderSell3,000$132.50$397,500.0013,950View SEC Filing  
6/1/2017Eric H SiegelEVPSell1,820$130.00$236,600.0018,744View SEC Filing  
5/31/2017Jean Jacques BienaimeDirectorBuy500$131.80$65,900.004,677View SEC Filing  
5/15/2017Jean Jacques BienaimeDirectorBuy500$115.00$57,500.004,177View SEC Filing  
5/8/2017Reid M HuberEVPSell8,577$119.21$1,022,464.1744,614View SEC Filing  
5/1/2017Eric H SiegelEVPSell1,820$124.73$227,008.6018,744View SEC Filing  
4/28/2017Jean Jacques BienaimeDirectorBuy500$124.26$62,130.003,677View SEC Filing  
4/13/2017Jean Jacques BienaimeDirectorBuy1,000$139.66$139,660.003,177View SEC Filing  
4/10/2017David W GryskaInsiderSell41,528$138.00$5,730,864.0020,754View SEC Filing  
4/10/2017Eric H SiegelEVPSell4,043$140.18$566,747.7419,008View SEC Filing  
4/7/2017Jean Jacques BienaimeDirectorBuy1,000$139.48$139,480.002,177View SEC Filing  
4/7/2017Steven H SteinEVPSell32,000$137.88$4,412,160.0041,648View SEC Filing  
3/17/2017Paul A FriedmanDirectorSell50,000$148.72$7,436,000.00302,976View SEC Filing  
1/9/2017Reid M. HuberEVPSell11,739$113.55$1,332,963.45View SEC Filing  
11/9/2016Reid M. HuberEVPSell2,715$109.95$298,514.25View SEC Filing  
10/20/2016Paula J SwainEVPSell10,000$90.00$900,000.0039,248View SEC Filing  
10/7/2016Barry P FlannellyEVPSell24,204$97.00$2,347,788.0013,595View SEC Filing  
9/23/2016Paula J SwainEVPSell20,000$90.00$1,800,000.0049,248View SEC Filing  
8/2/2016Reid M. HuberEVPSell10,000$87.96$879,600.00View SEC Filing  
7/29/2016Paula J SwainEVPSell60,000$90.00$5,400,000.0089,248View SEC Filing  
3/17/2016Julian BakerDirectorBuy800,000$63.98$51,184,000.0058,632View SEC Filing  
2/25/2016Julian BakerDirectorBuy64,290$70.79$4,551,089.10View SEC Filing  
2/16/2016Julian BakerDirectorBuy887,165$69.87$61,986,218.55View SEC Filing  
2/12/2016Julian BakerDirectorBuy2,251,427$63.53$143,033,157.31View SEC Filing  
1/15/2016Paula J. SwainEVPSell13,531$76.96$1,041,345.7623,693View SEC Filing  
1/6/2016Richard S. LevyEVPSell3,937$101.86$401,022.8216,926View SEC Filing  
12/7/2015Richard S. LevyEVPSell3,937$106.18$418,030.6616,926View SEC Filing  
11/18/2015Paul A. FriedmanDirectorSell225,000$113.83$25,611,750.00297,518View SEC Filing  
11/10/2015Eric H. SiegelEVPSell2,222$104.86$232,998.923,710View SEC Filing  
11/6/2015Richard S. LevyEVPSell3,936$116.51$458,583.3616,926View SEC Filing  
11/3/2015Yao WenqingEVPSell5,786$124.78$721,977.0821,371View SEC Filing  
10/13/2015Eric H. SiegelEVPSell2,222$101.49$225,510.783,355View SEC Filing  
10/6/2015Richard S. LevyEVPSell3,937$122.29$481,455.7316,926View SEC Filing  
9/21/2015Reid M. HuberEVPSell10,000$124.29$1,242,900.0062,865View SEC Filing  
9/16/2015Eric H. SiegelEVPSell2,222$130.69$290,393.183,355View SEC Filing  
9/11/2015Richard S LevyEVPSell4,301$130.00$559,130.0016,926View SEC Filing  
9/8/2015Richard S. LevyEVPSell3,937$118.90$468,109.3021,227View SEC Filing  
8/13/2015Eric H SiegelEVPSell2,222$107.69$239,287.18View SEC Filing  
7/15/2015Richard S LevyEVPSell70,217$120.00$8,426,040.00View SEC Filing  
7/14/2015Eric H SiegelEVPSell2,222$113.61$252,441.42View SEC Filing  
7/6/2015Richard S LevyEVPSell3,937$107.00$421,259.00View SEC Filing  
6/23/2015James M DalyEVPSell11,691$108.24$1,265,433.84View SEC Filing  
6/19/2015Richard S LevyEVPSell20,000$108.13$2,162,600.00View SEC Filing  
6/12/2015Eric H SiegelEVPSell2,223$105.31$234,104.13View SEC Filing  
6/8/2015Richard S LevyEVPSell3,937$107.58$423,542.46View SEC Filing  
5/27/2015Paul A FriedmanDirectorSell196,751$107.23$21,097,609.73View SEC Filing  
5/22/2015Paul A FriedmanDirectorSell102,243$108.22$11,064,737.46View SEC Filing  
5/14/2015Eric H SiegelEVPSell2,222$104.99$233,287.78View SEC Filing  
4/23/2015James M DalyEVPSell36,941$107.67$3,977,437.47View SEC Filing  
4/17/2015Yao WenqingEVPSell7,150$102.04$729,586.00View SEC Filing  
4/14/2015Eric H SiegelEVPSell2,222$98.72$219,355.84View SEC Filing  
4/13/2015Yao WenqingEVPSell23,000$95.18$2,189,140.00View SEC Filing  
4/7/2015Yao WenqingEVPSell20,031$90.13$1,805,394.03View SEC Filing  
3/30/2015Laurent ChardonnetVPSell113,776$93.64$10,653,984.64View SEC Filing  
3/30/2015Reid M HuberEVPSell34,263$93.66$3,209,072.58View SEC Filing  
3/12/2015Barry A ArikoDirectorSell80,000$89.27$7,141,600.00View SEC Filing  
3/12/2015Eric H SiegelEVPSell2,222$89.72$199,357.84View SEC Filing  
2/25/2015Eric H SiegelEVPSell13,333$85.00$1,133,305.00View SEC Filing  
2/24/2015James M DalyEVPSell11,112$82.19$913,295.28View SEC Filing  
2/17/2015Paula J SwainEVPSell17,500$76.90$1,345,750.00View SEC Filing  
1/26/2015Eric H SiegelEVPSell13,542$79.85$1,081,328.70View SEC Filing  
1/23/2015James M DalyEVPSell11,109$77.68$862,947.12View SEC Filing  
1/20/2015Paula J SwainEVPSell17,500$74.17$1,297,975.00View SEC Filing  
1/16/2015Richard S LevyEVPSell12,000$73.07$876,840.00View SEC Filing  
1/8/2015Eric H SiegelEVPSell15,626$75.00$1,171,950.00View SEC Filing  
1/6/2015Richard S LevyEVPSell25,000$71.84$1,796,000.00View SEC Filing  
1/5/2015Paula J SwainEVPSell17,500$73.90$1,293,250.00View SEC Filing  
12/23/2014James M DalyEVPSell11,113$74.43$827,140.59View SEC Filing  
12/2/2014Schutter Richard U DeChairmanSell50,000$74.89$3,744,500.00View SEC Filing  
11/6/2014Paul A FriedmanDirectorSell185,653$67.87$12,600,269.11View SEC Filing  
10/23/2014James M DalyEVPSell11,111$53.49$594,327.39View SEC Filing  
9/23/2014James M DalyEVPSell11,111$47.65$529,439.15View SEC Filing  
9/16/2014Richard S LevyEVPSell8,000$47.58$380,640.00View SEC Filing  
8/18/2014Richard S LevyEVPSell8,000$51.97$415,760.00View SEC Filing  
7/23/2014James M DalyEVPSell11,111$48.54$539,327.94View SEC Filing  
7/16/2014Richard S LevyEVPSell8,000$48.15$385,200.00View SEC Filing  
6/23/2014James M DalyEVPSell11,111$56.03$622,549.33View SEC Filing  
6/16/2014Richard S LevyEVPSell8,000$53.88$431,040.00View SEC Filing  
6/5/2014David C HastingsCFOSell200,000$52.73$10,546,000.00View SEC Filing  
5/23/2014James M DalyEVPSell11,111$48.48$538,661.28View SEC Filing  
5/16/2014Richard LevyEVPSell8,000$50.68$405,440.004,301View SEC Filing  
5/2/2014Laurent ChardonnetVPSell34,000$51.55$1,752,700.003,811View SEC Filing  
4/23/2014James DalyEVPSell30,555$47.71$1,457,779.05View SEC Filing  
2/20/2014Paul FriedmanDirectorSell33,354$63.51$2,118,312.54417,518View SEC Filing  
2/19/2014Paul FriedmanDirectorSell771,182$65.65$50,628,098.30417,518View SEC Filing  
2/19/2014Schutter Richard DeChairmanSell50,000$65.53$3,276,500.00155,000View SEC Filing  
2/18/2014David HastingsCFOSell275,000$65.86$18,111,500.008,500View SEC Filing  
9/10/2013Paul A FriedmanCEOSell376,789$37.32$14,061,765.48View SEC Filing  
9/9/2013Laurent ChardonnetVPSell44,834$37.31$1,672,756.54View SEC Filing  
9/6/2013David C HastingsCFOSell100,000$35.16$3,516,000.00View SEC Filing  
9/6/2013Richard S LevyEVPSell25,000$35.28$882,000.00View SEC Filing  
9/5/2013Paula J SwainEVPSell94,444$35.06$3,311,206.64View SEC Filing  
8/19/2013Roy WhitfieldDirectorSell50,000$26.70$1,335,000.00671,082View SEC Filing  
5/17/2013Roy A WhitfieldDirectorSell40,000$23.08$923,200.00View SEC Filing  
5/13/2013Richard S LevyEVPSell55,699$22.30$1,242,087.70View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Incyte (NASDAQ INCY) News Headlines

Source:
DateHeadline
FY2020 Earnings Forecast for Incyte Co. Issued By Oppenheimer (INCY)FY2020 Earnings Forecast for Incyte Co. Issued By Oppenheimer (INCY)
www.americanbankingnews.com - January 23 at 10:38 PM
BRIEF-Incyte Corp Recommends Shareholders Reject Mini-Tender Offer By TRC CapitalBRIEF-Incyte Corp Recommends Shareholders Reject Mini-Tender Offer By TRC Capital
www.reuters.com - January 23 at 5:22 PM
Incyte Corporation Recommends Shareholders Reject Mini-Tender Offer by TRC Capital CorporationIncyte Corporation Recommends Shareholders Reject Mini-Tender Offer by TRC Capital Corporation
finance.yahoo.com - January 23 at 5:22 PM
Oppenheimer Reiterates Hold Rating for Incyte (INCY)Oppenheimer Reiterates Hold Rating for Incyte (INCY)
www.americanbankingnews.com - January 22 at 11:16 PM
Brokers Issue Forecasts for Incyte Co.s FY2020 Earnings (INCY)Brokers Issue Forecasts for Incyte Co.'s FY2020 Earnings (INCY)
www.americanbankingnews.com - January 19 at 11:22 PM
Incyte Co. (INCY) Given Average Rating of "Buy" by BrokeragesIncyte Co. (INCY) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 19 at 11:04 AM
3 Biotech Stocks Start Healthy in ’18: Will the Rally Last?3 Biotech Stocks Start Healthy in ’18: Will the Rally Last?
finance.yahoo.com - January 18 at 3:24 PM
Zacks: Analysts Expect Incyte Co. (INCY) Will Post Quarterly Sales of $412.85 MillionZacks: Analysts Expect Incyte Co. (INCY) Will Post Quarterly Sales of $412.85 Million
www.americanbankingnews.com - January 18 at 5:38 AM
Incyte Co. (INCY) Expected to Post Earnings of -$0.50 Per ShareIncyte Co. (INCY) Expected to Post Earnings of -$0.50 Per Share
www.americanbankingnews.com - January 16 at 3:08 PM
Concert Pharma shares hit low note on patent challenge denialConcert Pharma shares hit low note on patent challenge denial
finance.yahoo.com - January 16 at 7:53 AM
Mid-Afternoon Market Update: Tuniu Gains After Announcing $100M Share Repurchase Program; Aradigm Shares Slide - NasdaqMid-Afternoon Market Update: Tuniu Gains After Announcing $100M Share Repurchase Program; Aradigm Shares Slide - Nasdaq
www.nasdaq.com - January 13 at 7:53 AM
Why Concert Pharmaceuticals, Inc. Is Singing the Blues TodayWhy Concert Pharmaceuticals, Inc. Is Singing the Blues Today
finance.yahoo.com - January 13 at 7:53 AM
Incyte: S&P 500’s Top Loser on January 11Incyte: S&P 500’s Top Loser on January 11
finance.yahoo.com - January 12 at 3:21 PM
The Biggest Loser: Incyte Slides 3.7%The Biggest Loser: Incyte Slides 3.7%
finance.yahoo.com - January 12 at 7:41 AM
Examining Incyte’s Quarterly Revenue TrendExamining Incyte’s Quarterly Revenue Trend
finance.yahoo.com - January 10 at 3:24 PM
Incyte Co. (INCY) Insider David W. Gryska Sells 6,760 SharesIncyte Co. (INCY) Insider David W. Gryska Sells 6,760 Shares
www.americanbankingnews.com - January 9 at 6:52 PM
Head to Head Contrast: Incyte (INCY) & Celator Pharmaceuticals (CPXX)Head to Head Contrast: Incyte (INCY) & Celator Pharmaceuticals (CPXX)
www.americanbankingnews.com - January 9 at 11:04 AM
5 Biggest New Drugs of 2018 -- and How You Can Profit From Their ... - Motley Fool5 Biggest New Drugs of 2018 -- and How You Can Profit From Their ... - Motley Fool
www.fool.com - January 9 at 8:20 AM
Incyte chief discusses company's latest cancer treatments...Incyte chief discusses company's latest cancer treatments...
finance.yahoo.com - January 9 at 8:20 AM
Incyte Co. Expected to Earn FY2022 Earnings of $8.02 Per Share (INCY)Incyte Co. Expected to Earn FY2022 Earnings of $8.02 Per Share (INCY)
www.americanbankingnews.com - January 8 at 8:40 PM
Celgenes $7 Billion Purchase Is Great For Drug Inventors. Is It Great For Celgene?Celgene's $7 Billion Purchase Is Great For Drug Inventors. Is It Great For Celgene?
www.forbes.com - January 8 at 11:11 AM
Incyte Co. Expected to Post Q1 2018 Earnings of ($0.33) Per Share (INCY)Incyte Co. Expected to Post Q1 2018 Earnings of ($0.33) Per Share (INCY)
www.americanbankingnews.com - January 8 at 5:04 AM
Incyte Co. (INCY) to Post FY2017 Earnings of ($1.00) Per Share, Oppenheimer ForecastsIncyte Co. (INCY) to Post FY2017 Earnings of ($1.00) Per Share, Oppenheimer Forecasts
www.americanbankingnews.com - January 5 at 8:14 AM
Q3 2018 EPS Estimates for Incyte Co. Boosted by Analyst (INCY)Q3 2018 EPS Estimates for Incyte Co. Boosted by Analyst (INCY)
www.americanbankingnews.com - January 4 at 1:40 PM
Is Incyte Corporation’s (NASDAQ:INCY) CEO Paid Enough To Stay Motivated?Is Incyte Corporation’s (NASDAQ:INCY) CEO Paid Enough To Stay Motivated?
finance.yahoo.com - January 4 at 7:40 AM
Insider Selling: Incyte Co. (INCY) EVP Sells 5,000 Shares of StockInsider Selling: Incyte Co. (INCY) EVP Sells 5,000 Shares of Stock
www.americanbankingnews.com - January 3 at 7:02 PM
Zacks Investment Research Downgrades Incyte (INCY) to SellZacks Investment Research Downgrades Incyte (INCY) to Sell
www.americanbankingnews.com - January 2 at 12:44 PM
 Analysts Anticipate Incyte Co. (INCY) Will Announce Quarterly Sales of $409.49 Million Analysts Anticipate Incyte Co. (INCY) Will Announce Quarterly Sales of $409.49 Million
www.americanbankingnews.com - January 1 at 3:00 AM
ValuEngine Downgrades Incyte (INCY) to SellValuEngine Downgrades Incyte (INCY) to Sell
www.americanbankingnews.com - December 31 at 2:18 PM
Zacks: Analysts Expect Incyte Co. (INCY) Will Announce Earnings of -$0.48 Per ShareZacks: Analysts Expect Incyte Co. (INCY) Will Announce Earnings of -$0.48 Per Share
www.americanbankingnews.com - December 30 at 7:08 PM
Short Interest in Incyte Co. (INCY) Expands By 18.2%Short Interest in Incyte Co. (INCY) Expands By 18.2%
www.americanbankingnews.com - December 30 at 2:34 AM
5 Immuno-Oncology Developments To Watch In 2018 - Forbes5 Immuno-Oncology Developments To Watch In 2018 - Forbes
www.forbes.com - December 26 at 1:06 PM
Incyte Co. (INCY) Receives Average Rating of "Buy" from AnalystsIncyte Co. (INCY) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - December 25 at 11:06 AM
3 Promising Cancer Immunotherapies to Watch in 2018 -- The ... - Motley Fool3 Promising Cancer Immunotherapies to Watch in 2018 -- The ... - Motley Fool
www.fool.com - December 24 at 1:47 AM
Invitae Chairman Randy Scott Joins Freenome Board of Directors ... - Business Wire (press release)Invitae Chairman Randy Scott Joins Freenome Board of Directors ... - Business Wire (press release)
www.businesswire.com - December 22 at 7:29 AM
3 Promising Cancer Immunotherapies to Watch in 20183 Promising Cancer Immunotherapies to Watch in 2018
finance.yahoo.com - December 22 at 7:29 AM
 Brokerages Anticipate Incyte Corporation (INCY) Will Post Quarterly Sales of $409.49 Million Brokerages Anticipate Incyte Corporation (INCY) Will Post Quarterly Sales of $409.49 Million
www.americanbankingnews.com - December 15 at 6:24 AM
Incyte (INCY) Now Covered by Deutsche BankIncyte (INCY) Now Covered by Deutsche Bank
www.americanbankingnews.com - December 12 at 10:06 PM
Incyte (INCY) Earns Buy Rating from Raymond James FinancialIncyte (INCY) Earns Buy Rating from Raymond James Financial
www.americanbankingnews.com - December 12 at 6:34 PM
Incyte (INCY) Reports Phase III Follow-Up Data for Jakafi - Yahoo FinanceIncyte (INCY) Reports Phase III Follow-Up Data for Jakafi - Yahoo Finance
finance.yahoo.com - December 12 at 7:39 AM
Four-Year Phase 3 Data Analysis Shows Durability of Response of Jakafi - Business Wire (press release)Four-Year Phase 3 Data Analysis Shows Durability of Response of Jakafi - Business Wire (press release)
www.businesswire.com - December 10 at 3:25 PM
Incyte (INCY) Downgraded by TheStreetIncyte (INCY) Downgraded by TheStreet
www.americanbankingnews.com - December 8 at 4:40 PM
Annual Gala Honoring MPN Heroes® - Business Wire (press release)Annual Gala Honoring MPN Heroes® - Business Wire (press release)
www.businesswire.com - December 8 at 3:22 PM
Incyte (INCY) Rating Reiterated by CowenIncyte (INCY) Rating Reiterated by Cowen
www.americanbankingnews.com - December 6 at 2:56 PM
MacroGenics Announces Closing of MGA012 Global Collaboration and License Agreement with Incyte - GlobeNewswire (press release)MacroGenics Announces Closing of MGA012 Global Collaboration and License Agreement with Incyte - GlobeNewswire (press release)
globenewswire.com - December 6 at 7:55 AM
Incyte Corporation (INCY) EVP Sells $68,214.96 in StockIncyte Corporation (INCY) EVP Sells $68,214.96 in Stock
www.americanbankingnews.com - December 5 at 7:34 PM
Incyte is Now Oversold (INCY)Incyte is Now Oversold (INCY)
www.nasdaq.com - December 4 at 3:22 PM
Incyte: Depressed Valuation With Catalysts Coming - Seeking AlphaIncyte: Depressed Valuation With Catalysts Coming - Seeking Alpha
seekingalpha.com - December 3 at 7:34 AM
Contrasting Incyte (INCY) and Roka Bioscience (ROKA)Contrasting Incyte (INCY) and Roka Bioscience (ROKA)
www.americanbankingnews.com - December 3 at 5:42 AM
Head to Head Comparison: Incyte (INCY) and Its CompetitorsHead to Head Comparison: Incyte (INCY) and Its Competitors
www.americanbankingnews.com - December 1 at 3:32 AM

SEC Filings

Incyte (NASDAQ:INCY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Incyte (NASDAQ:INCY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Incyte (NASDAQ INCY) Stock Chart for Wednesday, January, 24, 2018

Loading chart…

This page was last updated on 1/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.